{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T13:19:34Z","timestamp":1791638374605,"version":"4.3.4"},"reference-count":80,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100007229","name":"Harvard University","doi-asserted-by":"publisher","award":["1K12TR004381-01"],"award-info":[{"award-number":["1K12TR004381-01"]}],"id":[{"id":"10.13039\/100007229","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002081","name":"Irish Research Council","doi-asserted-by":"publisher","award":["GOIPG\/2023\/5216"],"award-info":[{"award-number":["GOIPG\/2023\/5216"]}],"id":[{"id":"10.13039\/501100002081","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007299","name":"Harvard Catalyst","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007299","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lipidjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical Lipidology"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.jacl.2026.03.019","type":"journal-article","created":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T07:05:23Z","timestamp":1775027123000},"page":"1054-1064","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Lipoprotein(a) reduction with inclisiran, alirocumab, evolocumab, enlicitide, and lerodalcibep: A systematic review and meta-analysis of randomized controlled trials"],"prefix":"10.1016","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2042-257X","authenticated-orcid":false,"given":"Martin D.","family":"Mulligan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3967-2715","authenticated-orcid":false,"given":"Rahul S.","family":"Gandhi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4847-3494","authenticated-orcid":false,"given":"Rishabh","family":"Vishwakarma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Romit","family":"Bhattacharya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"39","key":"10.1016\/j.jacl.2026.03.019_bib1","first-page":"3925","article-title":"Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement","volume":"43","author":"Kronenberg","year":"2022","journal-title":"Eur\u00a0Heart J"},{"issue":"4","key":"10.1016\/j.jacl.2026.03.019_bib2","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1001\/jamacardio.2023.5605","article-title":"Lipoprotein(a), C-reactive protein, and cardiovascular risk in primary and secondary prevention populations","volume":"9","author":"Small","year":"2024","journal-title":"JAMA Cardiol"},{"issue":"3","key":"10.1016\/j.jacl.2026.03.019_bib3","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/j.jacc.2023.09.836","article-title":"Per-particle cardiovascular risk of lipoprotein(a) vs non-Lp(a) apolipoprotein B-containing lipoproteins","volume":"83","author":"Marston","year":"2024","journal-title":"J Am Coll Cardiol"},{"issue":"18","key":"10.1016\/j.jacl.2026.03.019_bib4","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.1016\/j.jacc.2023.02.050","article-title":"Lipoprotein(a), oxidized phospholipids, and coronary artery disease severity and outcomes","volume":"81","author":"Gilliland","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacl.2026.03.019_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/j.atherosclerosis.2025.120420","article-title":"Effect of lipid-lowering therapies on lipoprotein(a) levels: a comprehensive meta-analysis of randomized controlled trials","volume":"408","author":"Xie","year":"2025","journal-title":"Atherosclerosis"},{"issue":"17","key":"10.1016\/j.jacl.2026.03.019_bib6","doi-asserted-by":"crossref","first-page":"13622","DOI":"10.3390\/ijms241713622","article-title":"Novel pharmacological therapies for the management of hyperlipoproteinemia(a)","volume":"24","author":"Kosmas","year":"2023","journal-title":"Int\u00a0J Mol Sci"},{"issue":"1","key":"10.1016\/j.jacl.2026.03.019_bib7","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1136\/heartjnl-2021-320708","article-title":"Lipoprotein(a): a risk factor for atherosclerosis and an emerging therapeutic target","volume":"109","author":"Di Fusco","year":"2023","journal-title":"Heart"},{"issue":"3","key":"10.1016\/j.jacl.2026.03.019_bib8","first-page":"397","article-title":"Lipoprotein(a) reduction with proprotein convertase subtilisin\/kexin type 9 inhibitors: a systematic review and meta-analysis","volume":"77","author":"Farmakis","year":"2021","journal-title":"J\u00a0Cardiovasc\u00a0Pharmacol"},{"key":"10.1016\/j.jacl.2026.03.019_bib9","article-title":"Efficacy and safety of proprotein convertase subtilisin\/kexin type 9 inhibitors as adjuvant treatments for patients with hypercholesterolemia treated with statin: a systematic review and network meta-analysis","volume":"13","author":"Huang","year":"2022","journal-title":"Front Pharmacol"},{"issue":"12","key":"10.1016\/j.jacl.2026.03.019_bib10","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0295359","article-title":"Proprotein convertase subtilisn\/kexin type 9 inhibitors and small interfering RNA therapy for cardiovascular risk reduction: a systematic review and meta-analysis","volume":"18","author":"Imran","year":"2023","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.jacl.2026.03.019_bib11","first-page":"911","article-title":"Inclisiran versus alirocumab in improving lipid profile parameters: a systematic review and meta-analysis","volume":"27","author":"Saad Cleto","year":"2025","journal-title":"Diabetes Obes\u00a0Metab"},{"issue":"12","key":"10.1016\/j.jacl.2026.03.019_bib12","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1002\/phar.2635","article-title":"Meta-analysis of clinical outcomes of PCSK9 modulators in patients with established ASCVD","volume":"41","author":"Talasaz","year":"2021","journal-title":"Pharmacotherapy"},{"issue":"2","key":"10.1016\/j.jacl.2026.03.019_bib13","first-page":"223","article-title":"Efficacy and safety of alirocumab and evolocumab as proprotein convertase subtilisin\/kexin type 9 (PCSK9) inhibitors in familial hypercholesterolemia: a systematic review and meta-analysis","volume":"31","author":"Ghasempour","year":"2024","journal-title":"Curr\u00a0Med Chem"},{"issue":"3","key":"10.1016\/j.jacl.2026.03.019_bib14","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1097\/FJC.0000000000001712","article-title":"Comparative efficacy of non-statin lipid-lowering therapies in patients with hypercholesterolemia at increased cardiovascular risk: an updated network meta-analysis","volume":"86","author":"Burnett","year":"2025","journal-title":"J Cardiovasc Pharmacol"},{"issue":"2","key":"10.1016\/j.jacl.2026.03.019_bib15","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.jacc.2019.10.057","article-title":"Effect of alirocumab on lipoprotein(a) and cardiovascular risk after acute coronary syndrome","volume":"75","author":"Bittner","year":"2020","journal-title":"J Am Coll Cardiol"},{"issue":"9","key":"10.1016\/j.jacl.2026.03.019_bib16","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1001\/jamacardio.2024.1659","article-title":"Efficacy and safety of lerodalcibep in patients with or at high risk of cardiovascular disease: a randomized clinical trial","volume":"9","author":"Klug","year":"2024","journal-title":"JAMA Cardiol"},{"issue":"2","key":"10.1016\/j.jacl.2026.03.019_bib17","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1001\/jama.2025.20620","article-title":"Efficacy and safety of oral PCSK9 inhibitor enlicitide in adults with heterozygous familial hypercholesterolemia: a randomized clinical trial","volume":"335","author":"Ballantyne","year":"2026","journal-title":"JAMA"},{"issue":"12","key":"10.1016\/j.jacl.2026.03.019_bib18","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1161\/CIRCULATIONAHA.118.037184","article-title":"Lipoprotein(a), PCSK9 inhibition, and cardiovascular risk: insights from the FOURIER trial","volume":"139","author":"O\u2019Donoghue","year":"2019","journal-title":"Circulation"},{"issue":"44","key":"10.1016\/j.jacl.2026.03.019_bib19","doi-asserted-by":"crossref","first-page":"4245","DOI":"10.1093\/eurheartj\/ehaa649","article-title":"Lipoprotein(a) lowering by alirocumab reduces the total burden of cardiovascular events independent of low-density lipoprotein cholesterol lowering: ODYSSEY OUTCOMES trial","volume":"41","author":"Szarek","year":"2020","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacl.2026.03.019_bib20","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.amjcard.2025.04.013","article-title":"The impact of inclisiran on lipid profiles in adults with hyperlipidemia: a meta-analysis and meta-regression of randomized controlled trials","volume":"250","author":"Khalil","year":"2025","journal-title":"Am\u00a0J\u00a0Cardiol"},{"issue":"6","key":"10.1016\/j.jacl.2026.03.019_bib21","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1056\/NEJMoa2511002","article-title":"A placebo-controlled trial of the oral PCSK9 inhibitor enlicitide","volume":"394","author":"Navar","year":"2026","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacl.2026.03.019_bib22","doi-asserted-by":"crossref","DOI":"10.3389\/fphys.2021.603910","article-title":"New insights into the regulation of lipoprotein metabolism by PCSK9: lessons from stable isotope tracer studies in human subjects","volume":"12","author":"Ying","year":"2021","journal-title":"Front Physiol"},{"issue":"10","key":"10.1016\/j.jacl.2026.03.019_bib23","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1002\/phar.2851","article-title":"Role of lipoprotein(a) in atherosclerotic cardiovascular disease: a review of current and emerging therapies","volume":"43","author":"Alhomoud","year":"2023","journal-title":"Pharmacotherapy"},{"issue":"4","key":"10.1016\/j.jacl.2026.03.019_bib24","doi-asserted-by":"crossref","first-page":"577","DOI":"10.3390\/ph16040577","article-title":"Inclisiran, low-density lipoprotein cholesterol and lipoprotein (a)","volume":"16","author":"Katsiki","year":"2023","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.jacl.2026.03.019_bib25","volume":"4","author":"Chandler","year":"2019"},{"key":"10.1016\/j.jacl.2026.03.019_bib26","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"issue":"1","key":"10.1016\/j.jacl.2026.03.019_bib27","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1186\/s13643-016-0384-4","article-title":"Rayyan\u2014a web and mobile app for systematic reviews","volume":"5","author":"Ouzzani","year":"2016","journal-title":"Syst Rev"},{"key":"10.1016\/j.jacl.2026.03.019_bib28","first-page":"37","article-title":"The revised Cochrane risk of bias tool for randomized trials (RoB 2) showed low interrater reliability and challenges in its application","volume":"126","author":"Minozzi","year":"2020","journal-title":"J\u00a0Clin\u00a0Epidemiol"},{"issue":"3","key":"10.1016\/j.jacl.2026.03.019_bib29","first-page":"261","article-title":"Bias and efficiency of meta-analytic variance estimators in the random-effects model","volume":"30","author":"Viechtbauer","year":"2005","journal-title":"J\u00a0Educ\u00a0Behav\u00a0Stat"},{"key":"10.1016\/j.jacl.2026.03.019_bib30","series-title":"The Handbook of Research Synthesis and Meta-Analysis","first-page":"295","article-title":"Analyzing effect sizes: random-effects models","author":"Raudenbush","year":"2009"},{"issue":"1","key":"10.1016\/j.jacl.2026.03.019_bib31","first-page":"55","article-title":"Methods to estimate the between-study variance and its uncertainty in meta-analysis","volume":"7","author":"Veroniki","year":"2016","journal-title":"Res\u00a0Synth\u00a0Methods"},{"issue":"7109","key":"10.1016\/j.jacl.2026.03.019_bib32","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ"},{"issue":"2","key":"10.1016\/j.jacl.2026.03.019_bib33","first-page":"367","article-title":"Simple heterogeneity variance estimation for meta-analysis","volume":"54","author":"Sidik","year":"2005","journal-title":"J\u00a0R\u00a0Stat\u00a0Soc\u00a0Ser\u00a0C\u00a0Appl\u00a0Stat"},{"issue":"3","key":"10.1016\/j.jacl.2026.03.019_bib34","doi-asserted-by":"crossref","first-page":"1","DOI":"10.18637\/jss.v036.i03","article-title":"Conducting meta-analyses in R with the metafor package","volume":"36","author":"Viechtbauer","year":"2010","journal-title":"J Stat Soft"},{"issue":"6","key":"10.1016\/j.jacl.2026.03.019_bib35","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1007\/s00125-019-4856-7","article-title":"Efficacy and safety of evolocumab in individuals with type 2 diabetes mellitus: primary results of the randomised controlled BANTING study","volume":"62","author":"Rosenson","year":"2019","journal-title":"Diabetologia"},{"issue":"20","key":"10.1016\/j.jacl.2026.03.019_bib36","doi-asserted-by":"crossref","first-page":"2570","DOI":"10.1016\/j.jacc.2020.03.025","article-title":"Evolocumab in HIV-infected patients with dyslipidemia: primary results of the randomized, double-blind BEIJERINCK study","volume":"75","author":"Boccara","year":"2020","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"10.1016\/j.jacl.2026.03.019_bib37","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1111\/dom.13680","article-title":"Randomised study of evolocumab in patients with type 2 diabetes and dyslipidaemia on background statin: primary results of the BERSON clinical trial","volume":"21","author":"Lorenzatti","year":"2019","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.jacl.2026.03.019_bib38","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.atherosclerosis.2021.06.913","article-title":"Alirocumab treatment and neurocognitive function according to the CANTAB scale in patients at increased cardiovascular risk: a prospective, randomized, placebo-controlled study","volume":"331","author":"Janik","year":"2021","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jacl.2026.03.019_bib39","unstructured":"A double-blind, randomized, placebo-controlled, multicenter study to evaluate long-term tolerability and durable efficacy of AMG 145 (Evolocumab) on LDL-C in hyperlipidemic subjects;\u00a0Published online January 18, 2012. Accessed January 5, 2012. https:\/\/clinicaltrials.gov\/study\/NCT01516879."},{"issue":"20","key":"10.1016\/j.jacl.2026.03.019_bib40","first-page":"2452","article-title":"Evolocumab for early reduction of LDL cholesterol levels in patients with acute coronary syndromes (EVOPACS)","volume":"74","author":"Koskinas","year":"2019","journal-title":"J\u00a0Am\u00a0Coll\u00a0Cardiol"},{"issue":"18","key":"10.1016\/j.jacl.2026.03.019_bib41","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and clinical outcomes in patients with cardiovascular disease","volume":"376","author":"Sabatine","year":"2017","journal-title":"N Engl J Med"},{"issue":"15","key":"10.1016\/j.jacl.2026.03.019_bib42","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1001\/jama.2016.3608","article-title":"Efficacy and tolerability of evolocumab vs ezetimibe in patients with muscle-related statin intolerance: the GAUSS-3 randomized clinical trial","volume":"315","author":"Nissen","year":"2016","journal-title":"JAMA"},{"issue":"22","key":"10.1016\/j.jacl.2026.03.019_bib43","doi-asserted-by":"crossref","first-page":"2373","DOI":"10.1001\/jama.2016.16951","article-title":"Effect of evolocumab on progression of coronary disease in statin-treated patients: the GLAGOV randomized clinical trial","volume":"316","author":"Nicholls","year":"2016","journal-title":"JAMA"},{"issue":"18","key":"10.1016\/j.jacl.2026.03.019_bib44","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1001\/jama.2014.4030","article-title":"Effect of evolocumab or ezetimibe added to moderate- or high-intensity statin therapy on LDL-C lowering in patients with hypercholesterolemia: the LAPLACE-2 randomized clinical trial","volume":"311","author":"Robinson","year":"2014","journal-title":"JAMA"},{"issue":"23","key":"10.1016\/j.jacl.2026.03.019_bib45","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1016\/j.jacc.2014.03.018","article-title":"Anti-PCSK9 monotherapy for hypercholesterolemia: the MENDEL-2 randomized, controlled phase III clinical trial of evolocumab","volume":"63","author":"Koren","year":"2014","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"10.1016\/j.jacl.2026.03.019_bib46","first-page":"758","article-title":"Efficacy and safety of alirocumab vs ezetimibe in statin-intolerant patients, with a statin rechallenge arm: the ODYSSEY ALTERNATIVE randomized trial","volume":"9","author":"Moriarty","year":"2015","journal-title":"J\u00a0Clin\u00a0Lipidol"},{"key":"10.1016\/j.jacl.2026.03.019_bib47","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.atherosclerosis.2016.08.043","article-title":"A phase III randomized trial evaluating alirocumab 300 mg every 4 weeks as monotherapy or add-on to statin: ODYSSEY CHOICE I","volume":"254","author":"Roth","year":"2016","journal-title":"Atherosclerosis"},{"issue":"9","key":"10.1016\/j.jacl.2026.03.019_bib48","article-title":"Efficacy and safety of alirocumab 150 mg every 4 weeks in patients with hypercholesterolemia not on statin therapy: the ODYSSEY CHOICE II study","volume":"5","author":"Stroes","year":"2016","journal-title":"J\u00a0Am Heart Assoc"},{"issue":"6","key":"10.1016\/j.jacl.2026.03.019_bib49","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1111\/dom.13257","article-title":"Alirocumab vs usual lipid-lowering care as add-on to statin therapy in individuals with type 2 diabetes and mixed dyslipidaemia: the ODYSSEY DM-DYSLIPIDEMIA randomized trial","volume":"20","author":"Ray","year":"2018","journal-title":"Diabetes Obes Metab"},{"issue":"12","key":"10.1016\/j.jacl.2026.03.019_bib50","first-page":"1781","article-title":"Efficacy and safety of alirocumab in insulin-treated individuals with type 1 or type 2 diabetes and high cardiovascular risk: the ODYSSEY DM-INSULIN randomized trial","volume":"19","author":"Leiter","year":"2017","journal-title":"Diabetes Obes\u00a0Metab"},{"issue":"1","key":"10.1016\/j.jacl.2026.03.019_bib51","first-page":"98","article-title":"ODYSSEY EAST: Alirocumab efficacy and safety vs ezetimibe in high cardiovascular risk patients with hypercholesterolemia and on maximally tolerated statin in China, India, and Thailand","volume":"14","author":"Han","year":"2020","journal-title":"J\u00a0Clin\u00a0Lipidol"},{"issue":"43","key":"10.1016\/j.jacl.2026.03.019_bib52","first-page":"2996","article-title":"ODYSSEY FH I and FH II: 78 week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemia","volume":"36","author":"Kastelein","year":"2015","journal-title":"Eur Heart J"},{"issue":"16","key":"10.1016\/j.jacl.2026.03.019_bib53","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1056\/NEJMoa1501031","article-title":"Efficacy and safety of alirocumab in reducing lipids and cardiovascular events","volume":"372","author":"Robinson","year":"2015","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.jacl.2026.03.019_bib54","first-page":"3140","article-title":"Alirocumab as add-on to atorvastatin versus other lipid treatment strategies: ODYSSEY OPTIONS I randomized trial","volume":"100","author":"Bays","year":"2015","journal-title":"J\u00a0Clin\u00a0Endocrinol\u00a0Metab"},{"issue":"22","key":"10.1016\/j.jacl.2026.03.019_bib55","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","article-title":"Alirocumab and cardiovascular outcomes after acute coronary syndrome","volume":"379","author":"Schwartz","year":"2018","journal-title":"New Engl J Med"},{"issue":"16","key":"10.1016\/j.jacl.2026.03.019_bib56","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1056\/NEJMoa1913805","article-title":"Inclisiran for the treatment of heterozygous familial hypercholesterolemia","volume":"382","author":"Raal","year":"2020","journal-title":"N Engl J Med"},{"issue":"16","key":"10.1016\/j.jacl.2026.03.019_bib57","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1912387","article-title":"Two phase 3 trials of inclisiran in patients with elevated LDL cholesterol","volume":"382","author":"Ray","year":"2020","journal-title":"N Engl J Med"},{"issue":"18","key":"10.1016\/j.jacl.2026.03.019_bib58","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1001\/jama.2022.5218","article-title":"Effect of alirocumab added to high-intensity statin therapy on coronary atherosclerosis in patients with acute myocardial infarction: the PACMAN-AMI randomized clinical trial","volume":"327","author":"R\u00c4ber","year":"2022","journal-title":"JAMA"},{"issue":"9965","key":"10.1016\/j.jacl.2026.03.019_bib59","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/S0140-6736(14)61399-4","article-title":"PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial","volume":"385","author":"Raal","year":"2015","journal-title":"Lancet"},{"issue":"20","key":"10.1016\/j.jacl.2026.03.019_bib60","doi-asserted-by":"crossref","first-page":"1939","DOI":"10.1016\/j.jacc.2024.03.382","article-title":"An \u201cinclisiran first\u201d strategy vs usual care in patients with atherosclerotic cardiovascular disease","volume":"83","author":"Koren","year":"2024","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"10.1016\/j.jacl.2026.03.019_bib61","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.amjcard.2015.10.021","article-title":"A phase 3 study of evolocumab (AMG 145) in statin-treated Japanese patients at high cardiovascular risk","volume":"117","author":"Kiyosue","year":"2016","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacl.2026.03.019_bib62","article-title":"Indirect comparison of the efficacy and safety of alirocumab and evolocumab on major cardiovascular events: a systematic review and network meta-analysis","volume":"16","author":"Xu","year":"2025","journal-title":"Front Pharmacol"},{"issue":"2","key":"10.1016\/j.jacl.2026.03.019_bib63","first-page":"129","article-title":"Inclisiran and cardiovascular events: a patient-level analysis of phase III trials","volume":"44","author":"Ray","year":"2023","journal-title":"Eur\u00a0Heart J"},{"issue":"16","key":"10.1016\/j.jacl.2026.03.019_bib64","first-page":"1553","article-title":"Phase 2b randomized trial of the oral PCSK9 inhibitor MK-0616","volume":"81","author":"Ballantyne","year":"2023","journal-title":"J\u00a0Am\u00a0Coll\u00a0Cardiol"},{"issue":"10","key":"10.1016\/j.jacl.2026.03.019_bib65","first-page":"873","article-title":"MK-0616: an oral PCSK9 inhibitor for hypercholesterolemia treatment","volume":"32","author":"Burnett","year":"2023","journal-title":"Expert Opin\u00a0Investig\u00a0Drugs"},{"issue":"40","key":"10.1016\/j.jacl.2026.03.019_bib66","first-page":"4272","article-title":"Long-term efficacy and safety of lerodalcibep in heterozygous familial hypercholesterolaemia: the LIBerate-HeFH trial","volume":"44","author":"Raal","year":"2023","journal-title":"Eur\u00a0Heart J"},{"issue":"10459","key":"10.1016\/j.jacl.2026.03.019_bib67","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/S0140-6736(24)01308-4","article-title":"Lipoprotein(a) and cardiovascular disease","volume":"404","author":"Nordestgaard","year":"2024","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.jacl.2026.03.019_bib68","first-page":"1576","article-title":"Emerging RNA therapeutics to lower blood levels of Lp(a)","volume":"77","author":"Tsimikas","year":"2021","journal-title":"J\u00a0Am\u00a0Coll\u00a0Cardiol"},{"issue":"5","key":"10.1016\/j.jacl.2026.03.019_bib69","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s11883-021-00918-3","article-title":"Lipid lowering drugs: present status and future developments","volume":"23","author":"Ruscica","year":"2021","journal-title":"Curr Atheroscler Rep"},{"issue":"7","key":"10.1016\/j.jacl.2026.03.019_bib70","first-page":"1085","article-title":"The future of lipid-lowering therapy","volume":"8","author":"Van Zwol","year":"2019","journal-title":"J\u00a0Clin Med"},{"issue":"2","key":"10.1016\/j.jacl.2026.03.019_bib71","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1007\/s40265-025-02274-x","article-title":"Effect of proprotein convertase subtilisin\/kexin type 9 (PCSK9) inhibitors on lipoprotein(a) levels: an umbrella review of meta-analyses of randomized controlled trials","volume":"86","author":"Qiao","year":"2026","journal-title":"Drugs"},{"issue":"5","key":"10.1016\/j.jacl.2026.03.019_bib72","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.jacc.2021.04.102","article-title":"Lipoprotein(a) and benefit of PCSK9 inhibition in patients with nominally controlled LDL cholesterol","volume":"78","author":"Schwartz","year":"2021","journal-title":"J Am Coll Cardiol"},{"issue":"10459","key":"10.1016\/j.jacl.2026.03.019_bib73","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/S0140-6736(24)01308-4","article-title":"Lipoprotein(a) and cardiovascular disease","volume":"404","author":"Nordestgaard","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.jacl.2026.03.019_bib74","unstructured":"U.S. Food and Drug Administration. Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book); Published online 2026. Accessed March 1, 2026. https:\/\/www.accessdata.fda.gov\/scripts\/cder\/ob\/index.cfm."},{"issue":"3","key":"10.1016\/j.jacl.2026.03.019_bib75","first-page":"385","article-title":"Lipoprotein(a) is markedly more atherogenic than LDL","volume":"83","author":"Bj\u00d6rnson","year":"2024","journal-title":"J\u00a0Am\u00a0Coll\u00a0Cardiol"},{"issue":"16","key":"10.1016\/j.jacl.2026.03.019_bib76","first-page":"1633","article-title":"Clinical trial design for lipoprotein(a)-lowering therapies","volume":"81","author":"Malick","year":"2023","journal-title":"J\u00a0Am\u00a0Coll\u00a0Cardiol"},{"issue":"1","key":"10.1016\/j.jacl.2026.03.019_bib77","doi-asserted-by":"crossref","first-page":"e48","DOI":"10.1161\/ATV.0000000000000147","article-title":"Lipoprotein(a): a genetically determined, causal, and prevalent risk factor for atherosclerotic cardiovascular disease: a scientific statement from the American Heart Association","volume":"42","author":"Reyes-Soffer","year":"2022","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"10155","key":"10.1016\/j.jacl.2026.03.019_bib78","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1016\/S0140-6736(18)31652-0","article-title":"Baseline and on-statin treatment lipoprotein(a) levels for prediction of cardiovascular events: individual patient-data meta-analysis of statin outcome trials","volume":"392","author":"Willeit","year":"2018","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.jacl.2026.03.019_bib79","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1056\/NEJMoa1905239","article-title":"Lipoprotein(a) reduction in persons with cardiovascular disease","volume":"382","author":"Tsimikas","year":"2020","journal-title":"N Engl J Med"},{"issue":"23","key":"10.1016\/j.jacl.2026.03.019_bib80","doi-asserted-by":"crossref","first-page":"1992","DOI":"10.1001\/jama.2024.21957","article-title":"Zerlasiran\u2014a small-interfering RNA targeting lipoprotein(a): a phase 2 randomized clinical trial","volume":"332","author":"Nissen","year":"2024","journal-title":"JAMA"}],"container-title":["Journal of Clinical Lipidology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287426000917?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287426000917?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T17:49:47Z","timestamp":1782496187000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1933287426000917"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":80,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S1933287426000917"],"URL":"https:\/\/doi.org\/10.1016\/j.jacl.2026.03.019","relation":{},"ISSN":["1933-2874"],"issn-type":[{"value":"1933-2874","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Lipoprotein(a) reduction with inclisiran, alirocumab, evolocumab, enlicitide, and lerodalcibep: A systematic review and meta-analysis of randomized controlled trials","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical Lipidology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacl.2026.03.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 National Lipid Association. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}